Nektar Therapeutics (NASDAQ: NKTR) — Perfil da empresa, notícias e dados financeiros
Nektar Therapeutics focuses on discovering innovative medicines for oncology, pain management, and autoimmune diseases.
Nektar Therapeutics
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company focused on discovering and developing innovative medicines in areas of high unmet medical need. The company's research and development portfolio is primarily concentrated on oncology, pain management, and autoimmune diseases. By leveraging its proprietary technology platforms, Nektar aims to create therapies that improve patient outcomes and quality of life. Their projects range from preclinical research to late-stage clinical trials, with the objective to bring new, effective treatments to market. Through strategic collaborations and partnerships, Nektar Therapeutics seeks to expand its pipeline and accelerate the development of novel therapeutics.
Resumo
Operações
Produtos e/ou serviços de Nektar Therapeutics
- NKTR-214 (bempegaldesleukin): Immunotherapy candidate for cancer, aiming to stimulate the patient's immune system to identify and attack cancer cells.
- NKTR-358 (LY3471851): Potential treatment for autoimmune and inflammatory disorders, promoting the body's natural immune tolerance mechanisms.
- NKTR-255: Designed to enhance the body's natural defenses against cancer and viral infections by increasing natural killer cells and CD8+ T cells.
- NKTR-181: A novel opioid analgesic developed to reduce the abuse potential associated with conventional opioids.
- NKTR-262: A small molecule agonist intended to activate the immune system to detect and destroy cancer cells as part of a combination therapy with bempegaldesleukin.
- NKTR-105: Docetaxel encapsulated in a polymer conjugate, aimed at enhancing the delivery and efficacy of the chemotherapy while reducing its side effects.
equipe executiva do Nektar Therapeutics
- Howard W. RobinCEO, President & Director
- Jonathan ZalevskySenior VP and Chief Research & Development Officer
- Linda M. RubinsteinCFO and Principal Financial & Accounting Officer
- Jason BarnardChief Accounting Officer
- Elizabeth ZhangVP of Legal, Corporate Counsel & Secretary
- Spilios AsimakopoulosVice President of Commercial Strategy & Marketing
- Robert BacciChief People Officer and Head of Quality & Facilities
- Jennifer RuddockChief Business Officer
- Mary TagliaferriChief Medical Officer
- Ken FrankeSenior Vice President of Biologics Process Development & Manufacturing
Últimas notícias sobre a Nektar Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Nektar Therapeutics, em USD.
- Cap. de mercado
- 1,3 bi
- Receita (TTM)
- 54,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -19.0
- Dividend yield
- —
- Margem de lucro
- -287.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 55,2 mi | -130,8 mi | -164,1 mi | |
| 98,4 mi | -105,2 mi | -119 mi | |
| 90,1 mi | -137,4 mi | -276,1 mi | |
| 92,1 mi | -240,2 mi | -368,2 mi |